Post-authorisation Safety Study in Patients With Type 2 Diabetes Mellitus to Assess the Risk of Acute Liver Injury, Acute Kidney Injury and Chronic Kidney Disease, Severe Complications of Urinary Tract Infection, Genital Infections, and Diabetic Ketoacidosis Among Patients Treated With Empagliflozin Compared to Patients Treated With Other SGLT2 Inhibitors or DPP-4 Inhibitors

Trial Profile

Post-authorisation Safety Study in Patients With Type 2 Diabetes Mellitus to Assess the Risk of Acute Liver Injury, Acute Kidney Injury and Chronic Kidney Disease, Severe Complications of Urinary Tract Infection, Genital Infections, and Diabetic Ketoacidosis Among Patients Treated With Empagliflozin Compared to Patients Treated With Other SGLT2 Inhibitors or DPP-4 Inhibitors

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 09 Apr 2018

At a glance

  • Drugs Empagliflozin (Primary) ; Antihyperglycaemics; Sulfonylureas
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 03 Apr 2018 Planned End Date changed from 1 Jul 2018 to 1 Jan 2020.
    • 03 Apr 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Jan 2020.
    • 19 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top